VistaGen Therapeutics (VTGN) Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder - StreetInsider.com

Submitted by Anonymous (not verified) on Wed, 11/30/2022 - 13:32

VistaGen Therapeutics (VTGN) Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder StreetInsider.com

Log in to post comments